First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI).

Daniel P. Petrylak,Xin Gao,Nicholas J. Vogelzang,Mary Harlow Garfield,Ian W. Taylor,Marcia Dougan Moore,Ronald Peck,Howard A. Burris

First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI).

2020

Daniel P. Petrylak
Xin Gao
Nicholas J. Vogelzang
Mary Harlow Garfield
Ian W. Taylor
Marcia Dougan Moore
Ronald Peck
Howard A. Burris

3500Background: Proteolysis Targeting Chimera (PROTAC) protein degraders induce selective degradation of targeted proteins by engaging the ubiquitin proteasome system. ARV-110 is an orally bioavail...

Keywords:

Oncology
Castrate-resistant prostate cancer
Abiraterone
Enzalutamide
first in human
phase i study
Internal medicine
in patient
Pathology
Androgen receptor
Medicine
Cancer research
Proteasome
Proteolysis targeting chimera

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations